Pinned post
With all the new data regarding first line treatments for patients with metastatic EGFR mutation positive lung cancer at #ASCO2024 this is an important paper regarding the role of TP53 co-mutations and mixed/discordant responses to treatment with EGFR TKI. So pleased it’s out! 1/2
Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in @NatureComms. nature.com/articles/s4146… 🧵View quoted post on X